M G von Herrath

Summary

Affiliation: The Scripps Research Institute
Country: USA

Publications

  1. ncbi Tolerance induction with agonist peptides recognized by autoaggressive lymphocytes is transient: therapeutic potential for type 1 diabetes is limited and depends on time-point of administration, choice of epitope and adjuvant
    M G von Herrath
    Depts of Immunology and Neuropharmacology, IMM6, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037, USA
    J Autoimmun 16:193-9. 2001
  2. ncbi Obstacles to identifying viruses that cause autoimmune disease
    M G von Herrath
    Department of Neuropharmacology, Division of Virology, IMM6, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla CA 92037, USA
    J Neuroimmunol 107:154-60. 2000
  3. ncbi Vaccination to treat persistent viral infection
    M G von Herrath
    Division of Virology, Department of Neuropharmacology, The Scripps Research Institute, 10550 N Torrey Pines Road, La Jolla, California, 92037, USA
    Virology 268:411-9. 2000
  4. pmc Thymic tolerance to only one viral protein reduces lymphocytic choriomeningitis virus-induced immunopathology and increases survival in perforin-deficient mice
    M Von Herrath
    Department of Neuropharmacology, Division of Virology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 73:5918-25. 1999
  5. ncbi In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes
    M G von Herrath
    Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Immunol 161:5087-96. 1998
  6. ncbi Pathological changes in the islet milieu precede infiltration of islets and destruction of beta-cells by autoreactive lymphocytes in a transgenic model of virus-induced IDDM
    M Von Herrath
    Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Autoimmun 10:231-8. 1997
  7. ncbi Low-affinity cytotoxic T-lymphocytes require IFN-gamma to clear an acute viral infection
    M G von Herrath
    Department of Neuropharmacology, Scripps Research Institute, La Jolla, California 92037, USA
    Virology 229:349-59. 1997
  8. pmc Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice
    M G von Herrath
    Department of Neuropharmacology, Scripps Research Institute, La Jolla, California 92037, USA
    J Clin Invest 98:1324-31. 1996
  9. ncbi Protection from type 1 diabetes in the face of high levels of activated autoaggressive lymphocytes in a viral transgenic mouse model crossed to the SV129 strain
    M G von Herrath
    Immunology and Neuropharmacology, The Scripps Research Institute, La Jolla, California 92121, USA
    Diabetes 50:2700-8. 2001
  10. ncbi A dual role for TNF-alpha in type 1 diabetes: islet-specific expression abrogates the ongoing autoimmune process when induced late but not early during pathogenesis
    U Christen
    Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Immunol 166:7023-32. 2001

Collaborators

Detail Information

Publications25

  1. ncbi Tolerance induction with agonist peptides recognized by autoaggressive lymphocytes is transient: therapeutic potential for type 1 diabetes is limited and depends on time-point of administration, choice of epitope and adjuvant
    M G von Herrath
    Depts of Immunology and Neuropharmacology, IMM6, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037, USA
    J Autoimmun 16:193-9. 2001
    ....
  2. ncbi Obstacles to identifying viruses that cause autoimmune disease
    M G von Herrath
    Department of Neuropharmacology, Division of Virology, IMM6, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla CA 92037, USA
    J Neuroimmunol 107:154-60. 2000
    ..Potential pathogenetic mechanisms and their impact on devising the best strategy to prove such an association will be discussed. These thoughts might also be important for applying new immune interventions in type I diabetes or MS...
  3. ncbi Vaccination to treat persistent viral infection
    M G von Herrath
    Division of Virology, Department of Neuropharmacology, The Scripps Research Institute, 10550 N Torrey Pines Road, La Jolla, California, 92037, USA
    Virology 268:411-9. 2000
    ..Thus, our results establish that CTL can be generated in persistently infected mice and that a crucial factor for clearing viral infection is the affinity of the CTL...
  4. pmc Thymic tolerance to only one viral protein reduces lymphocytic choriomeningitis virus-induced immunopathology and increases survival in perforin-deficient mice
    M Von Herrath
    Department of Neuropharmacology, Division of Virology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 73:5918-25. 1999
    ..Thus, "selective reduction" of the antiviral immune response to only one viral protein can significantly reduce inflammatory immunopathology and might be a therapeutic possibility for certain nonlytic infections...
  5. ncbi In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes
    M G von Herrath
    Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Immunol 161:5087-96. 1998
    ..This study demonstrates that in vivo treatment with a MHC class I blocking peptide can prevent autoimmune disease by directly affecting expansion of autoreactive CTL...
  6. ncbi Pathological changes in the islet milieu precede infiltration of islets and destruction of beta-cells by autoreactive lymphocytes in a transgenic model of virus-induced IDDM
    M Von Herrath
    Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Autoimmun 10:231-8. 1997
    ..Thus, beta-cell destruction by activated autoreactive lymphocytes is a multifactorial process that is likely to require changes within the islet milieu or dysfunction of islets...
  7. ncbi Low-affinity cytotoxic T-lymphocytes require IFN-gamma to clear an acute viral infection
    M G von Herrath
    Department of Neuropharmacology, Scripps Research Institute, La Jolla, California 92037, USA
    Virology 229:349-59. 1997
    ..Thus, IFN-gamma is required for clearing an acute viral infection in the absence of a high-affinity CTL response. In the absence of IFN-gamma persistent viral infection results despite the presence of low-affinity CTL...
  8. pmc Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice
    M G von Herrath
    Department of Neuropharmacology, Scripps Research Institute, La Jolla, California 92037, USA
    J Clin Invest 98:1324-31. 1996
    ..The majority of lymphocytes in the islets of insulin-treated tg mice without IDDM produces IL-4, IL-10, and TGF-beta. In contrast, lymphocytes from islets of tg mice developing IDDM mainly make gamma-IFN...
  9. ncbi Protection from type 1 diabetes in the face of high levels of activated autoaggressive lymphocytes in a viral transgenic mouse model crossed to the SV129 strain
    M G von Herrath
    Immunology and Neuropharmacology, The Scripps Research Institute, La Jolla, California 92121, USA
    Diabetes 50:2700-8. 2001
    ..This finding has important implications for interpreting numbers and pathogenicity of autoreactive lymphocytes in prediabetic patients of genetically diverse backgrounds...
  10. ncbi A dual role for TNF-alpha in type 1 diabetes: islet-specific expression abrogates the ongoing autoimmune process when induced late but not early during pathogenesis
    U Christen
    Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Immunol 166:7023-32. 2001
    ..This observation has importance for understanding the complex role of inflammatory cytokines in autoimmunity...
  11. ncbi Disruption of the STAT4 signaling pathway protects from autoimmune diabetes while retaining antiviral immune competence
    A Holz
    Department of Neuropharmacology, Division of Virology, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Immunol 163:5374-82. 1999
    ..Selective inhibition of the STAT4 signal transduction pathway might constitute a novel and attractive approach to prevent clinical insulin-dependent diabetes mellitus in prediabetic individuals at risk...
  12. ncbi How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model
    M G von Herrath
    Department of Neuropharmacology, Scripps Research Institute, La Jolla, California 92037
    Immunity 1:231-42. 1994
    ..Their anti-self (viral) CD8+ CTL were of lower affinity and avidity than CD8+ CTL generated by nontransgenic controls. Disease was dependent on T cell help, since deletion of CD4+ cells completely circumvented the IDDM...
  13. pmc CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge
    M G von Herrath
    Department of Neuropharmacology, Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 70:1072-9. 1996
    ....
  14. ncbi Regulation of virally induced autoimmunity and immunopathology: contribution of LCMV transgenic models to understanding autoimmune insulin-dependent diabetes mellitus
    M G von Herrath
    Division of Virology, Department of Neuropharmacology, IMM6, Scripps Research Institute, 10550 N Torrey Pines Road, La Jolla, CA 92037, USA
    Curr Top Microbiol Immunol 263:145-75. 2002
  15. pmc 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: viruses, autoimmunity and immunoregulation
    C M Filippi
    La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA
    Clin Exp Immunol 160:113-9. 2010
    ..Induction of immunoregulatory mechanisms, and in particular the phenotype and function of T(regs), is of interest therapeutically and will be discussed...
  16. pmc Immunology in the clinic review series: focus on type 1 diabetes and viruses: the role of viruses in type 1 diabetes: a difficult dilemma
    K T Coppieters
    Type 1 Diabetes Center, The La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    Clin Exp Immunol 168:5-11. 2012
    ..More profound insights into the intricate relationship between viruses and their autoimmunity-prone host may lead ultimately to opportunities for early intervention through immune modulation or vaccination...
  17. pmc Incidental CD8 T cell reactivity against caspase-cleaved apoptotic self-antigens from ubiquitously expressed proteins in islets from prediabetic human leucocyte antigen-A2 transgenic non-obese diabetic mice
    K T Coppieters
    Type 1 Diabetes Center, The La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    Clin Exp Immunol 165:155-62. 2011
    ..HHD model...
  18. ncbi Role of viruses in the loss of tolerance to self-antigens and in autoimmune diseases
    M G von Herrath
    Scripps Research Institute, Dept of Neuropharmacology, La Jolla, CA 92037, USA
    Trends Microbiol 3:424-30. 1995
    ..Recent results with animal models of insulin-dependent diabetes provide insight into how viruses induce autoimmune disease...
  19. pmc Anti-thymoglobulin (ATG) treatment does not reverse type 1 diabetes in the acute virally induced rat insulin promoter-lymphocytic choriomeningitis virus (RIP-LCMV) model
    D Bresson
    Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    Clin Exp Immunol 163:375-80. 2011
    ..Our data would argue for the use of multiple animal models to assess efficacy of promising immune-based interventions and select the most potent therapies for future clinical trials...
  20. doi Emerging immune therapies in type 1 diabetes and pancreatic islet transplantation
    D A Schneider
    Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA
    Diabetes Obes Metab 15:581-92. 2013
    ..Analysing the foundation and the results of the most current T1D immunotherapeutic trials, this article gives an outlook for future directions of the field...
  21. ncbi IL-10 and the resolution of infections
    C M Filippi
    La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA
    J Pathol 214:224-30. 2008
    ....
  22. ncbi Design of immune-based interventions in autoimmunity and viral infections--the need for predictive models that integrate time, dose and classes of immune responses
    M G von Herrath
    Division of Virology, The Scripps Research Institute, LaJolla, CA 92037, USA
    Novartis Found Symp 239:16-24; discussion 24-30, 45-51. 2001
    ..Consequently, there is a strong need for models that can predict the outcome of immune-based interventions taking these considerations into account...
  23. ncbi The cholera toxin B subunit is a mucosal adjuvant for oral tolerance induction in type 1 diabetes
    S Bregenholt
    Islet Discovery Research, Novo Nordisk, Bagsvaerd, Denmark
    Scand J Immunol 57:432-8. 2003
    ..The data presented here demonstrate that CTB, even in its unconjugated form, functions as a mucosal adjuvant, increasing the specific tolerogenic effect of oral insulin...
  24. pmc Coupling of oral human or porcine insulin to the B subunit of cholera toxin (CTB) overcomes critical antigenic differences for prevention of type I diabetes
    J S Petersen
    La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
    Clin Exp Immunol 134:38-45. 2003
    ..Thus, our findings delineate a pathway to overcome issues in oral antigen choice for prevention of type I diabetes...
  25. ncbi Structural and functional identification of major histocompatibility complex class I-restricted self-peptides as naturally occurring molecular mimics of viral antigens. Possible role in CD8+ T cell-mediated, virus-induced autoimmune disease
    D Hudrisier
    Institut de Pharmacologie et de Biologie Structurale, CNRS, 205 route de Narbonne, 31400 Toulouse, France
    J Biol Chem 276:19396-403. 2001
    ....